Market Closed -
Nasdaq
04:00:00 2025-02-07 pm EST
5-day change
1st Jan Change
66.91 USD
-1.95%
-1.79%
-12.75%
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
January 13, 2025 at 03:23 am EST
Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing
Jan. 13
MT
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
Jan. 13
MT
Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing
Jan. 07
MT
Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says
Dec. 10
MT
UBS Raises Price Target on Arcellx to $114 From $106, Maintains Buy Rating
Dec. 10
MT
Arcellx, Inc. - Special Call
Dec. 09
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Dec. 09
MT
Sector Update: Health Care
Dec. 09
MT
Arcellx, Inc. Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed or Refractory Multiple Myeloma to Be Presented During an Oral Presentation At the 66Th Ash Annual Meeting and Exposition
Dec. 09
CI
Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate
Dec. 09
MT
Arcellx Insider Sold Shares Worth $1,242,170, According to a Recent SEC Filing
Nov. 13
MT
Truist Boosts Price Target on Arcellx to $136 From $87, Keeps Buy Rating
Nov. 12
MT
Earnings Flash (ACLX) ARCELLX Posts Q3 Revenue $26M
Nov. 07
MT
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 07
CI
Morgan Stanley Adjusts Arcellx's Price Target to $106 From $81, Keeps Overweight Rating
Nov. 06
MT
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Nov. 05
CI
Redburn Initiates Arcellx at Buy With $109 Price Target
24-10-08
MT
Arcellx Insider Sold Shares Worth $1,840,053, According to a Recent SEC Filing
24-09-04
MT
Cantor Fitzgerald Initiates Arcellx at Overweight
24-09-03
MT
UBS Trims Price Target on Arcellx to $77 From $78, Maintains Buy Rating
24-08-12
MT
Earnings Flash (ACLX) ARCELLX Reports Q2 Revenue $27.4M
24-08-08
MT
Arcellx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
24-08-08
CI
Arcellx Insider Sold Shares Worth $1,208,435, According to a Recent SEC Filing
24-08-02
MT
Arcellx Insider Sold Shares Worth $1,102,668, According to a Recent SEC Filing
24-06-14
MT
Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target
24-05-31
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
ACLX: Dynamic Chart
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
More about the company
Last Close Price
66.91 USD
Average target price
116.38 USD
Spread / Average Target
+73.93%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1